Programmed cell death protein blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation in an adolescent patient
Irtiza Sheikh(The University of Texas MD Anderson Cancer Center), Branko Cuglievan(The University of Texas MD Anderson Cancer Center), Michael Roth(National Coalition for Cancer Survivorship), César Núñez(Universidad de Medellín), David McCall(The University of Texas MD Anderson Cancer Center)
Cited by 0
Related Papers
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
|Nature Reviews Clinical Oncology|2018|237
Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|67
Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
|Cancers|2021|66
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer
|Nature Reviews Clinical Oncology|2021|59
Developing national cancer survivorship standards to inform quality of care in the United States using a consensus approach
|Journal of Cancer Survivorship|2024|55